DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
CERC-301 is an investigational drug.
There have been 6 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Massachusetts General Hospital.
There are seven US patents protecting this investigational drug and eighty-one international patents.
Recent Clinical Trials for CERC-301
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Cerecor Inc||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||National Institute on Drug Abuse (NIDA)||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Office of Research on Women's Health (ORWH)||Phase 2|
Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CERC-301||Start Trial||Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists||Rugen Holdings (Cayman) Limited (Grand Cayman, KY)||Start Trial|
|CERC-301||Start Trial||Compounds, compositions and methods||CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)||Start Trial|
|CERC-301||Start Trial||3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists||RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)||Start Trial|
|CERC-301||Start Trial||Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists||Rugen Holdings (Cayman) Limited (Grand Cayman, KY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|